AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05447195
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment in this study is divided into four periods. Period 1 (W1-W6) is the triple therapy period in which subjects in both groups will be given placebo + RT + TMZ. Period 2 (W7-W10) is the treatment-free (rest) period in which subjects do not receive any study drug/therapy. Period 3 (W11-W58) is the placebo+TMZ maintenance therapy period in which subjects in both groups are given placebo+TMZ. Period 4 (after W59) is the monotherapy period in which subjects are given placebo IV infusion weekly until disease progression.
Trial: NCT06252870
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 15 mg/m² on Day+1 after graft (=Day0) 10 mg/m² 3 days on Day+4/Day+6/Day+11 after graft (=Day0)
Trial: NCT06252870
Drug: Post-Transplant Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/kg intravenous 2 days on Day+3/Day+5 after graft (=Day0)
Trial: NCT06252870
Drug: Cycophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conditioning regimen: 14.5 mg/kg intravenous 2 days on Day-6/Day-5 before graft (=Day0)
Trial: NCT05925452
Drug: GenaKumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GenaKumab 3.0mg/kg dose group : GenaKumab 3.0 mg/kg, Subcutaneous injection, Q4w； GenaKumab 4.0 mg/kg dose group : GenaKumab 4.0 mg/kg, Subcutaneous injection, Q4w
Trial: NCT05386550
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive 3 cycles of oral solution of placebo matched to Xevinapant (Debio 1143) once daily from Day 1 to 14 per 3-week cycle in combination with radiotherapy followed by 3 cycles of monotherapy of placebo matched to Xevinapant (Debio 1143) from Day 1 to 14, per 3-week cycle (Each cycle is of 3 weeks).
Trial: NCT06329063
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of placebo (oral spray)
Trial: NCT05587231
Drug: Dextenza 0.4Mg Ophthalmic Insert
RxNorm normalized name: Dextenza 0.4mg Ophthalmic Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The experimental group will have the Dextenza Insert implanted immediately after surgery
Trial: NCT05202574
Drug: Intravenous drug
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous drug injection
Trial: NCT04137588
Drug: Antiangiogenesis Agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: antiangiogenesis agents plus chemotherapy as first line treatment
Trial: NCT04987996
Drug: GR-MD-02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive up to seventeen doses of GR-MD-02 intravenously over 85 Days.
Trial: NCT04987996
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive up to seventeen doses of placebo intravenously over 85 Days.
Trial: NCT00260767
Drug: HEC placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00754949
Drug: 1% Azithromycin and 0.1% Dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
Trial: NCT00754949
Drug: 1% Azithromycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
Trial: NCT06151587
Drug: QLM3004 Concentration 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of QLM3004 Ophthalmic Solution~1 drop in each eye at bedtime
Trial: NCT06151587
Drug: QLM3004 Concentration 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose of QLM3004 Ophthalmic Solution~1 drop in each eye at bedtime
Trial: NCT06151587
Drug: QLM3004 Concentration 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of QLM3004 Ophthalmic Solution~1 drop in each eye at bedtime
Trial: NCT04739618
Drug: Keytruda Injectable Product
RxNorm normalized name: Keytruda Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PD-1 inhibitor antibody
Trial: NCT04739618
Drug: Yervoy Injectable Product
RxNorm normalized name: Yervoy Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-CTLA-4 antibody
Trial: NCT06372522
Drug: Pitocin Injectable Product
RxNorm normalized name: Pitocin Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The primary dose of oxytocin is 1.0 mU/min, with an incremental increase by 2.5 mU/min every 30 minutes, until 20.0 mU/min, tittered to a target of 3-5 contractions in a 10-minute period, or active labor (dilatation \> 6 cm).
Trial: NCT06252961
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 5 days
Trial: NCT05406219
Drug: BAY2395840
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release (IR) tablet, oral administration
Trial: NCT05978492
Drug: TXN10128
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants receive TXN10128 capsules orally once daily.
Trial: NCT05804656
Drug: CKDB-501A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection CKDB-501A
Trial: NCT05804656
Drug: Botox®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection Botox®
Trial: NCT04847752
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the dosage and duration
Trial: NCT04847752
Drug: PCSK9 inhibitor
RxNorm normalized name: PCSK9 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the dosage and duration
Trial: NCT05859412
Drug: Steroid injection (Depomedrone 40mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid injection (Depomedrone 40mg) into the carpal tunnel as per standard practice in patients with carpal tunnel syndrome
Trial: NCT04775862
Drug: investigator choice re-challenge with anti EGFR Rx
RxNorm normalized name: Re-Covr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upon second progression, patients will be enrolled into the study as per inclusion criteria and consent, and a cfDNA blood test will be drawn, and RAS status will be examined. If RAS is wildtype, then the investigator will decide whether to re-challenge with an anti EGFR antibody , or give SOC third line chemotherapy (Regorafenib or TAS-102).
Trial: NCT05981001
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide will be administered at 60 mg/kg IV daily over approximately two hours for two days. Cyclophosphamide will be initiated seven days prior to the anticipated LNL transfer, and the precise timing will depend on the rate of in vitro LNL growth.
Trial: NCT04945707
Drug: Ferric Derisomaltose 1000 Mg in 100 mL INTRAVENOUS SOLUTION [Monoferric]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferric derisomaltose (Monoferric) 1000 mg X1 (for subject \<50 kg, 20 mg/kg
Trial: NCT04945707
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline
Trial: NCT06014606
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral formulation
Trial: NCT04752566
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered via IV infusion once a week for 4 weeks.
Trial: NCT06132477
Drug: GLP-1 receptor agonist
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized to continue or discontinue GLP-1 receptor agonists after bariatric surgery
Trial: NCT05237791
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline 100ml (loading dose for 10 minutes), 15mg/kg/hr (continuous infusion)
Trial: NCT05577312
Drug: BRL-101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD34 + autologous hematopoietic stem and progenitor cells edited at the BCL11A enhancer site
Trial: NCT05105750
Drug: aspirin 100 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100mg aspirin for at least 3 days followed by aspirin 100 mg/d
Trial: NCT05043792
Drug: TT-00920 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TT-00920 Placebo Tablets
Trial: NCT05158335
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single SC dose or repeated SC doses of placebo.
Trial: NCT05411588
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05249933
Drug: Deyou; Beijing Tide Pharmaceutical Co, China, containing 20,000 iu pronase granules combined with 1 g NaHCO3 to maintain the intragastric PH at 6-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drink Deyo with 200ml warm water 25 minutes before swallowing the capsule to remove mucus in the stomach.
Trial: NCT04955223
Drug: Yinhu Qingwen Granules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For mild and common patients, take 1 bag 2 times a day. For severe patients, take 1 bag 3 times a day.
Trial: NCT05680480
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive placebo weekly in addition to SOC for 48 weeks.
Trial: NCT04580368
Drug: CFTR Modulators
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants with rare mutations will receive active therapy in N-of-1 design with participants serving as their own control
Trial: NCT05699993
Drug: IBI351
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI351 was administered orally
Trial: NCT06601517
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single dose; Administered orally
Trial: NCT06601517
Drug: HDM1002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT06604546
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 IU group D1:Placebo+500 ml Lactated Ringer's (LR)(Subject's left or right leg)； D2:Placeboe+250 ml Lactated Ringer's (LR)(Subject's left or right arm)； D3:Placebo+500 ml Normal Saline (NS)(Subject's left or right leg)； 385 IU group D1:Placebo+250 ml Lactated Ringer's (LR)(Subject's left or right arm)； 1500 IU group D1:Placebo+250 ml Lactated Ringe's (LR)(Subject's left or right arm).
Trial: NCT06592495
Drug: Period 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWJ1589 or DWC202315
Trial: NCT06592495
Drug: Period 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWJ1589 or DWC202315
Trial: NCT06592495
Drug: Period 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DWJ1589 or DWC202315
Trial: NCT06608329
Drug: HDM1002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, administered orally. The study is a randomized, open-label, single dose, 3-period, 3 sequence, crossover design.
Trial: NCT04942015
Drug: Placebo of Honghuaruyi Wan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Honghuaruyi Wan simulation agent. Made of starch,dextrin and edible pigment from Tibet Qizheng Tibetan Medicine Co.,Ltd. ( Pill (15 pills/plate ×2 plates/box))
Trial: NCT05434065
Drug: Celecoxib 200mg
RxNorm normalized name: CELECOXIB 200MG CAP
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Using celecoxib (200 mg/day) for 21 days starting within 6 hours after onset of ICH
Trial: NCT06609070
Drug: CHG0521 Oral Coating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will receive an oral coating of CHG0521 in the form of drops, in addition to the clinician\&#39;s standard treatment regimen, for a duration of 6 months or until confirmed progression, unacceptable toxicity, or any criteria for withdrawal from the trial.
Trial: NCT05392790
Drug: Calcium and Vit D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional medical treatment in the form of Calcium, Vit D and Bi phosphnate.
Trial: NCT05969756
Drug: Conventional etch and rinse sealant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thirty-eight permanent molars will receive conventional etch and rinse sealant
Trial: NCT05145764
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encapsulated placebo (matched for color, weight, and size)
Trial: NCT05453942
Drug: SAR441566
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated dose of SAR441566 administered twice a day (BID) for 4 weeks under fed conditions
Trial: NCT05453942
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated dose of matching placebo administered twice a day (BID) for 4 weeks under fed condition
Trial: NCT05498233
Drug: Doxylamine + Pyridoxine
RxNorm normalized name: doxylamine / pyridoxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of R or T drug in each of 2 periods of the study in fasted conditions
Trial: NCT04960930
Drug: FMX101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topically once daily
Trial: NCT05108454
Drug: Multiple micronutrient supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple Micronutrient Supplements (MMS) is a nutritional supplement for use during pregnancy based on United Nations International Multiple Micronutrient Antenatal Preparation (UNIMMAP) formulation following WHO specification. It contains 15 micronutrients including Iron and Folic Acid (IFA) at dosages that approximate the recommended dietary allowances for pregnancy.
Trial: NCT06009237
Drug: Placebo for ABBV-903
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet; oral
Trial: NCT04742348
Drug: Carbidopa Levodopa
RxNorm normalized name: carbidopa / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who are randomized to active drug group will receive 1 dose of immediate release carbidopa-levodopa (50mg/500mg) .
Trial: NCT04742348
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who are randomized to placebo group will be provided with similar looking tablet(s) as the active drug.
Trial: NCT05460364
Drug: BR1018-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group A : One tablet of BR1018-1 administered alone once daily for 9 days.~Treatment group C : One tablet each of BR1018-1 and BR1018-2 administered in combination once daily for 9 days.
Trial: NCT05460364
Drug: BR1018-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group B : One tablet of BR1018-2 administered alone once daily for 9 days.~Treatment group C : One tablet each of BR1018-1 and BR1018-2 administered in combination once daily for 9 days.
Trial: NCT05893771
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound guided genicular nerve infiltration with 20 ml normal saline as a placebo control.
Trial: NCT05098938
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral (upper gum area), 1 table.
Trial: NCT04999215
Drug: F-choline intravenous injection
RxNorm normalized name: choline Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive one injection of F-choline before undergoing hybrid PET/CT imaging per standard procedures. F-choline PET examinations may be repeated, if this judged to be in the patient's best interest by his referring physician and the study staff, up to a maximum 4 examinations per year.
Trial: NCT04765644
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two 200 mg capsules per day (400 mg/day) for 7 days
Trial: NCT04488159
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet
Trial: NCT04488159
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Infusion
Trial: NCT04488159
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Infusion
Trial: NCT05889442
Drug: Levcromakalim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of 20 mL levcromakalim (0.05 mg/min (50 μg/ mL) over 20 minutes
Trial: NCT05125718
Drug: 0.85% synthetic antimicrobial peptide TAPS-18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: commercially available synthetic antimicrobial peptide gel for periodontal disease treatment
Trial: NCT05125718
Drug: 0.9% normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: commercially available normal saline Sodium Chloride irrigation solution
Trial: NCT06505941
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-cell-containing placebo
Trial: NCT05688215
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05688215
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05688215
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05465798
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients allocated to this arm will receive a matching placebo similar to MC 3x3 pills used in the intervention arm. Placebos will be delivered orally every day for up to three consecutive days.
Trial: NCT06439433
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once a week for 6 weeks
Trial: NCT03418649
Drug: Eplerenone 50 Mg Tab
RxNorm normalized name: eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg PO per day for 10 days
Trial: NCT03418649
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO once daily for 10 days
Trial: NCT05005845
Drug: NFX-179 gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NFX-179 topical gel is the active investigational product being studied
Trial: NCT05005845
Drug: Vehicle gel
RxNorm normalized name: vehicle gel base no.61
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NFX-179 vehicle gel is the placebo comparator for this study
Trial: NCT05247970
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching capsule to S-309309 administered orally
Trial: NCT06174688
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular Injections
Trial: NCT04992065
Drug: NNC0385-0434 A 15 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg administered as one oral tablet once daily in the morning in a fasting state. The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day. The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).
Trial: NCT04992065
Drug: NNC0385-0434 A 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg administered as one oral tablet once daily in the morning in a fasting state. The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day. The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).
Trial: NCT04992065
Drug: NNC0385-0434 A 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg administered as one oral tablet once daily in the morning in a fasting state.~The tablet should be taken at least 30 min before the first food, beverage or other oral medications of the day.~The tablet can be taken with up to half a glass of water (approximately 120 mL/ 4 fluid ounces).
Trial: NCT05201430
Drug: FOLFOXIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: irinotecan\* 165 mg/m² iv continue for 1.5 hours, D1 oxaliplatin 85 mg/m² iv continue for 2 hours, D1 leucovorin 400 mg/m² iv continue for 2 hours, D1 5-FU 2400\~3200 mg/m² cont. inf. 48h, D1 repeat every 2 weeks (Q2W)
Trial: NCT05201430
Drug: CapeOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxaliplatin 130 mg/m2 iv continue for 2 hours, D1 capecitabine 1000mg/m2/d PO Bid, once every morning and evening D1-14 repeat every 3 weeks (Q3W)
Trial: NCT05136274
Drug: Medical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The surgical treatment group can be laparoscopically or by laparotomy, using the Linear Salpingostomy technique. Follow-up with β fraction of chorionic gonadotropin on days 0, 3, 7 and 14 together with gynecological abdominal or transvaginal ultrasound on day 0 and 7 and hysterosalpingography will be performed after three months of treatment.
Trial: NCT06241638
Drug: Vitamin B12 0.5 MG/ACTUAT
RxNorm normalized name: vitamin B12 0.5 MG/ACTUAT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigators measured the blood levels of Vitamin B12 and HbA1c as well as the BMI in two study groups; The Experimental group: Vitamin B12 and Dapagliflozin group and Active Comparator group: Dapagliflozin group.~The Dapagliflozin group received only Dapagliflozin 10 mg/daily orally for twelve months, whereas, the Vitamin B12 and Dapagliflozin group received Vit. B12 supplements methylcobalamin 500 µg once daily orally with the anti-diabetic therapy Dapagliflozin 10 mg/daily orally for twelve months.
Trial: NCT05723432
Drug: KD6001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KD6001 will be administered intravenously.
Trial: NCT04809818
Drug: LT3001 drug product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of LT3001 drug product administered by intravenous infusion
Trial: NCT04809818
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of Placebo administered by intravenous infusion
Trial: NCT05639153
Drug: DR30303
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DR30303 dose level of escalation IV every 3 weeks (Q3W) Day 1, as well as dose expansion with recommended dose level from dose escalation.
Trial: NCT06193408
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsule
Trial: NCT04720716
Drug: IBI310
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI310 IV d1, Q6W